Ischemic stroke, i.e. irreversible damage of a part of the patient's brain, is caused by the formation of blood clot in the major vessel which gives blood supply to a certain part of the brain. At early time, within the first 4,5 hours, the conventional treatment is to try to dissolve this blood clot with a medication ("thrombolytic drug") which is administered to the blood through the needle in the vein. If the clot still remains there, additional treatment is possible - going directly to the clot via artery and taking it out with a special device. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reasons. The purpose of the present study is to evaluate the benefit and safety efficacy of thrombectomy and standard stroke care in clinical routine treatment of acute occlusive stroke compared to standard stroke care only.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
341
Thrombectomy by selected stent retrievers (TREVO, Solitaire, pREset, in special cases all stent retrievers) as additional therapy in major artery occlusion in patients fulfilling criteria for and receiving intravenous thrombolysis
Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
Karolinska University Hospital
Stockholm, Sweden
Categorical shift in modified Rankin Scale score at 3 months
Categorical shift towards better stroke outcome as reflected by lower, i.e. better, Rankin Scale scores over the range of the scale in active compared to control group.
Time frame: 90 (range 76-104) days from stroke onset
Functional independence at 3 months after stroke onset
Proportion of patients with functional independence (modified Rankin Scale, mRS, score 0-2) at 3 months after stroke onset
Time frame: 90 (76-104) days after stroke onset
Excellent recovery at 3 months
Proportion of patients with excellent outcome (mRS score 0-1) at 3 months
Time frame: 90 (76-104) days after stroke onset
Length of in-hospital stay
Days to discharge from in-hospital ward to home/secondary care for survivors in thrombectomy vs. control
Time frame: 90 (76-104) days after stroke onset
Home time stay
Number of days the patient stayed at home or at relative's stay within the first 3 months after stroke onset, in thrombectomy vs. control
Time frame: 90 (76-104) days after stroke onset
Recurrent stroke within 3 months
Time frame: 90 (76-104) days after stroke onset
Recanalisation of the occluded artery for thrombectomy treated population
Recanalisation of the occluded artery for thrombectomy treated population, defined as at least TICI 2b flow in the treated territory after procedure
Time frame: 6h
Time to revascularisation
Time from stroke onset to revascularisation to any TICI (Thrombolysis in Cerebral Infarction) grade (2b-3 by core lab evaluation) for the actively treated population
Time frame: 6h
Recanalisation of the occluded artery at 24h computerized tomography angiography /contrast-enhanced magnetic resonance angiography
Defined as AOL 2-3
Time frame: 22-36h
Proportion of patients with recanalisation before thrombectomy
Defined as AOL 2-3
Time frame: 6h
Reduction of infarct size
Reduction in infarct size (thrombectomy vs. control) at 22-36 hours
Time frame: 22-36h
Neurological and functional improvement in relation to thrombus length
Neurological improvement (difference in National Institute of Health Stroke Scale from baseline to 12h, to 24h and to 7D after initiation of intravenous thrombolysis, or discharge if earlier), and functional outcome at 3 months in relation to recanalisation status and thrombus length (mm)
Time frame: 90 (76-104) days
All-cause mortality at 3 months
Time frame: 90 (76-104) days
Neurological death within 7 days post treatment
Time frame: 7 days
Distal embolism/reocclusion demonstrated by follow-up computerized tomography angiography /contrast-enhanced magnetic resonance angiography
Distal embolism/reocclusion will be evaluated by DSA immediately following the endovascular intervention and at the 22-36 hour follow up CT and CTA scans. The proportion of patients with recanalisation of the target occlusion and distal enbolism/reocclusion will be calculated.
Time frame: 22-36h
Embolism into new territories (ENT)
Time frame: 22-36h
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.